| Literature DB >> 32447486 |
Hai-Zhen Zhu1, Chun-Ju Fang1, Yi Guo2, Qi Zhang1, Li-Min Huang1, Dong Qiu1, Guang-Peng Chen3, Xiu-Feng Pang4, Jian-Jun Hu5, Jian-Guo Sun6, Zheng-Tang Chen7.
Abstract
PURPOSE: Currently, the routine screening program has insufficient capacity for the early diagnosis of lung cancer. Therefore, a type of chitosan-molecular beacon (CS-MB) probe was developed to recognize the miR-155-5p and image the lung cancer cells for the early diagnosis.Entities:
Keywords: Chitosan; Lung cancer; MicroRNA; Molecular beacon; Molecular imaging; Tumor-initiating cell
Year: 2020 PMID: 32447486 PMCID: PMC7324423 DOI: 10.1007/s00432-020-03246-2
Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN: 0171-5216 Impact factor: 4.553
Fig. 1Schematic showing the delivery of miR-155-5p MB into the cells via CS nanoparticles for the detection and imaging of miRNA
Fig. 2Fluorescence imaging and detection in viable cancer cells. a Confocal microscopy imaging of the four cells after delivery of the miR-155-5p MB (red) by CS nanoparticles. RS MB was used as a negative control. The cell nucleuses were stained by Hoechst33342 (blue). Scale bar = 25 μm. b Fluorescence intensity of Cy5 was measured after imaging (n = 6) (*p < 0.05). c Relative miR-155-5p expression was detected in A549, SPC-A1, H446 cells, and TICs by qRT-PCR
Fig. 3Establishment of animal models and detection of miR-155-5p expression. a HE staining in A549 and H446 lung xenograft(LX)models (× 200). b HE staining at 4, 6, 8, and 12 weeks in transgenic mice models after instillation of adenovirus (× 400). c, d miR-155-5p expression in the subcutaneous xenografts (SX) and lung xenografts (LX) of nude mice models (n = 8). e miR-155-5p expression in transgenic mice at different disease stages (n = 8) (*p < 0.05)
Fig. 4In vivo identification of miR-155-5p and fluorescence imaging of cancer cells in xenografts models. a Imaging the subcutaneous and lung xenografts after injection of CS-MB via the tail veins. Subcutaneous xenografts model, a: A549 treated with CS-RS MB, b:A549 treated with CS-miR-155-5p MB, c: H446 treated with CS-miR-155-5p MB. Lung xenografts model, d: A549 treated with CS-RS MB, e:A549 treated with CS-miR-155-5p MB, f: H446 treated with CS-miR-155-5p MB. Groups a and d were used as the negative controls. b Imaging the xenografts after removal. c Fluorescence intensity was analyzed after injection (n = 8) (*p < 0.05). d Confocal microscopy imaging of the xenografts tissues after transfection with CS-miR155-5p MB or CS-RS MB (red). Cell nuclei were stained by DAPI (blue). Scale bar 25, 50 μm. Arrow: planting nodule and cancer cells
Fig. 5In vivo identification of miR-155-5p and fluorescence imaging of cancer cells in transgenic mice at different stages of the disease. a Imaging the lung after injection of CS-miR-155-5p MB nanoparticles via the tail vein. Mice without intranasal inhalation of the adenovirus were used as the control group. b Imaging the lungs after removal. c Fluorescence intensity was analyzed after injection (n = 8) (*p < 0.05). d Confocal microscopy imaging of the different pathological changes after transfection with CS-miR-155-5p MB. Cell nuclei were stained by DAPI (blue). Scale bar 50 μm. Arrow ①: atypical hyperplasia. Arrow ②: adenoma. Arrow③: carcinoma in situ. Arrow ④: adenocarcinoma
Fig. 6Identification of miR-155-5p and fluorescence imaging of the cancer cells in human lung squamous carcinoma and adenocarcinoma tissues. RS MB was used as a negative control. Scale bar 50 μm